Publications by authors named "Stephane Ferretti"

Claim this Profile
D
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Stephane Ferretti, Jacques Hamon, Ruben de Kanter, Clemens Scheufler, Rita Andraos-Rey

Nature· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.
Alan Zhang, Katherine Seiss, Laurent Laborde, Sebastian Palacio-Ramirez, Daniel Guthy, Stephane Ferretti

Bioconjug Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Stephane Ferretti

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, Chia-Chi Lin, Richard Quek, Stephane Ferretti

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Sebastian Bauer, George D Demetri, Ensar Halilovic, Reinhard Dummer, Christophe Meille, Stephane Ferretti

Br J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.
Laura Israël, Anton Glück, Marjorie Berger, Marine Coral, Melanie Ceci, Stéphane Ferretti

Oncogenesis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAX8 and MECOM are interaction partners driving ovarian cancer.
Melusine Bleu, Fanny Mermet-Meillon, Verena Apfel, Louise Barys, Laura Holzer, Stephane Ferretti

Nat Commun· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201.
Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, Claire Fabre, Christophe Meille

AAPS J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 dynamics vary between tissues and are linked with radiation sensitivity.
Jacob Stewart-Ornstein, Yoshiko Iwamoto, Miles A Miller, Mark A Prytyskach, Stephane Ferretti

Nat Commun· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.
Verena Apfel, Damien Begue, Valentina Cordo', Laura Holzer, Laetitia Martinuzzi, Stephane Ferretti

ACS Pharmacol Transl Sci· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models.
Kathleen Sprouffske, Grainne Kerr, Cheng Li, Anirudh Prahallad, Ramona Rebmann, Stéphane Ferretti

Comput Struct Biotechnol J· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Donglim Esther Park, Jingwei Cheng, Christian Berrios, Joan Montero, Marta Cortés-Cros, Stéphane Ferretti

Proc Natl Acad Sci U S A· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A Chapeau

Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Andrea Vaupel, Philipp Holzer, Stephane Ferretti, Vito Guagnano, Joerg Kallen

Bioorg Med Chem Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
Terrence F Meehan, Nathalie Conte, Theodore Goldstein, Giorgio Inghirami, Mark A Murakami, Stephane Ferretti

Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf mouse model.
Emilie A Chapeau, Agnieszka Gembarska, Eric Y Durand, Emeline Mandon, Claire Estadieu, Stephane Ferretti

Proc Natl Acad Sci U S A· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.
Thomas Horn, Stéphane Ferretti, Nicolas Ebel, Angela Tam, Samuel Ho

Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito

Elife· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Hui Gao, Joshua M Korn, Stéphane Ferretti, John E Monahan, Youzhen Wang

Nat Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Philipp Holzer, Keiichi Masuya, Pascal Furet, Joerg Kallen, Therese Valat-Stachyra, Stéphane Ferretti

J Med Chem· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito

Elife· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Stephane Ferretti

Mol Cancer Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.
Claudia Weidensteiner, Peter R Allegrini, Melanie Sticker-Jantscheff, Vincent Romanet, Stephane Ferretti

BMC Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.
Marta Cortés-Cros, Christelle Hemmerlin, Stephane Ferretti, Juan Zhang, John S Gounarides

Proc Natl Acad Sci U S A· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.
Paul M J McSheehy, Claudia Weidensteiner, Catherine Cannet, Stephane Ferretti, Didier Laurent

Clin Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis